TherapeuticsMD, Inc. (TXMD) News
Filter TXMD News Items
TXMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TXMD News From Around the Web
Below are the latest news stories about THERAPEUTICSMD INC that investors may wish to consider to help them evaluate TXMD as an investment opportunity.
TherapeuticsMD Announces Third Quarter 2023 Financial ResultsBOCA RATON, Fla., November 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. |
TherapeuticsMD Announces Second Quarter 2023 Financial ResultsBOCA RATON, Fla., August 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. |
TherapeuticsMD Announces First Quarter 2023 Financial ResultsBOCA RATON, Fla., May 15, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. |
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuyTherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionBOCA RATON, Fla., April 07, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. |
TherapeuticsMD Completes Transaction to License Its Products to Mayne PharmaBOCA RATON, Fla., January 03, 2023--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products |